Ali Nilufar, Wolf Cody, Kanchan Swarna, Veerabhadraiah Shivakumar R, Bond Laura, Turner Matthew W, Jorcyk Cheryl L, Hampikian Greg
Boise State University.
University of Utah.
Res Sq. 2023 Jun 28:rs.3.rs-3097552. doi: 10.21203/rs.3.rs-3097552/v1.
Nullomers are the shortest strings of absent amino acid (aa) sequences in a species or group of species. Primes are those nullomers that have not been detected in the genome of any species. 9S1R is a 5-aa peptide derived from a prime sequence that is tagged with 5 arginine aa, used to treat triple negative breast cancer (TNBC) in an in vivo TNBC mouse model. 9S1R is administered in trehalose (9S1R-NulloPT), which enhances solubility and exhibits some independent effects against tumor growth and is thus an important component in the drug preparation.
We examined the effect of 9S1R-NulloPT on tumor growth, metabolism, metastatic burden, necrosis, tumor immune microenvironment, and the transcriptome of aggressive mouse TNBC tumors.
The peptide-treated mice had smaller tumors in the initial phase of the treatment, as compared to the untreated control, and reduced in vivo bioluminescence at later stages, which is indicative of metabolically inactive tumors. A decrease in ex vivo bioluminescence was also observed in the excised tumors of treated mice, but not in the secondary metastasis in the lungs. The treatment also caused changes in tumor immune microenvironment with increased infiltration of immune cells and margin inflammation. The treatment upregulated 365 genes and downregulated 710 genes in tumors compared to the untreated group. Consistent with in vitro findings in breast cancer cell lines, downregulated genes in the treated TNBC tumors include Cellular Metabolic Process Related genes (179), specifically mitochondrial genes associated with TCA cycle/oxidative phosphorylation (44), and translation machinery/ribosome biogenesis genes (45). Among upregulated genes, the Developmental Pathway (13), ECM Organization (12) and Focal Adhesion Related Pathways (7) were noteworthy. We also present data from a pilot study using a bilateral BC mouse model, which supports our findings.
In conclusion, although 9S1R-NulloPT was moderate at reducing the tumor volume, it altered the tumor immune microenvironment as well as the tumor transcriptome, rendering tumors metabolically less active by downregulating the mitochondrial function and ribosome biogenesis. This corroborates previously published in vitro findings.
无效肽段是指在一个物种或一组物种中不存在的最短氨基酸(aa)序列串。原肽是指在任何物种的基因组中都未检测到的无效肽段。9S1R是一种由原肽序列衍生而来的5氨基酸肽,其带有5个精氨酸氨基酸标签,用于在体内三阴性乳腺癌(TNBC)小鼠模型中治疗三阴性乳腺癌。9S1R以海藻糖(9S1R-NulloPT)给药,海藻糖可提高溶解度,并对肿瘤生长具有一些独立的抑制作用,因此是药物制剂中的重要成分。
我们研究了9S1R-NulloPT对侵袭性小鼠TNBC肿瘤的肿瘤生长、代谢、转移负担、坏死、肿瘤免疫微环境和转录组的影响。
与未治疗的对照组相比,肽处理的小鼠在治疗初期肿瘤较小,后期体内生物发光降低,这表明肿瘤代谢不活跃。在处理小鼠的切除肿瘤中也观察到离体生物发光降低,但在肺部的继发性转移中未观察到。该治疗还导致肿瘤免疫微环境发生变化,免疫细胞浸润增加和边缘炎症。与未治疗组相比,该治疗使肿瘤中的365个基因上调,710个基因下调。与乳腺癌细胞系的体外研究结果一致,经处理的TNBC肿瘤中下调的基因包括细胞代谢过程相关基因(179个),特别是与三羧酸循环/氧化磷酸化相关的线粒体基因(44个),以及翻译机制/核糖体生物发生基因(45个)。在上调的基因中,发育途径(13个)、细胞外基质组织(12个)和粘着斑相关途径(7个)值得注意。我们还展示了一项使用双侧乳腺癌小鼠模型的初步研究数据,该数据支持我们的发现。
总之,虽然9S1R-NulloPT在减小肿瘤体积方面效果一般,但它改变了肿瘤免疫微环境以及肿瘤转录组,通过下调线粒体功能和核糖体生物发生使肿瘤代谢活性降低。这证实了先前发表的体外研究结果。